Western Suburbs Cancer Clinical Trials

Cancer Clinical Trials

Western Suburbs Cancer Clinical Trials

If you or someone you love is facing cancer, clinical trials may provide an alternative. Northwestern Medicine offers clinical studies right in your community for a wide variety of types and stages of cancer. These research studies are designed to test new ways to diagnose, treat and prevent cancer, as well as to manage symptoms and side effects of the disease.

Clinical trials have played an important role in the fight against cancer. They are the only scientific way to prove whether a new treatment works better than current treatments. Most of the approaches that doctors use to treat cancer today would never have become available without clinical trials.

Current Central DuPage Hospital, Delnor Hospital and Kishwaukee Hospital Cancer Clinical Trials

Currently, there are a wide variety of oncology clinical trials available through physicians on the medical staffs of Northwestern Medicine Central DuPage HospitalNorthwestern Medicine Delnor Hospital and Northwestern Medicine Kishwaukee Hospital. For ease of searching, the trials are sorted into the following categories:

  • Bladder
  • Blood, Bone & Tissue
  • Brain
  • Breast
  • Colorectal
  • Esophageal
  • Kidney
  • Liver
  • Lung
  • Pancreatic
  • Prostate
  • Women's Reproductive System
  • Other Cancers

If you find a clinical trial that interests you, talk with your physician or call 630.933.6528. TTY 711.

View Trials

Study: Chemoradiotherapy with or w/o Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer.
Clinical Trial #: S1806
NCT Number: NCT03775265
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas
Clinical Trial #: A051902
NCT#: NCT04803201
Principal Investigator: Jonathan Moreira, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements
Clinical Trial #: S1918
NCT#: NCT04799275
Principal Investigator: Reem Karmali, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Clinical Trial #: COG ANHL1931 NU
NCT#: NCT04759586
Principal Investigator: Reem Karmali, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Clinical Trial #: S1925
NCT Number: NCT04269902
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A phase 1/1b adaptive dose escalation study of mycophenolate mofetil (MMF) in combination with standard of care for patients with glioblastoma
Clinical Trial #: NU 21C01
NCT#: NCT05236036
Principal Investigator: Priya Kumthekar, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Clinical Trial #: NRG-BN012
NCT#: NCT05438212
Principal Investigator: Dr. Magill
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Safety and tolerability of MW151 administered with hippocampal avoidant whole brain radiation therapy (HA-WBRT) in patients with brain metastases
Clinical Trial #: MW151-102 ImmunoChem
NCT#: NCT05417282
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Clinical Trial #: NRG-CC009
Principal Investigator: Dr. Sachdev
Contact: Research Office 630.933.7820


Study: A Phase 2, single arm, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma
Clinical Trial #: NU 16C02
NCT#: NCT02847559
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase 1-2 Dose-Escalation and Expansion Study of ST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors
Clinical Trial #: SAPIENCE ST101-101
NCT#: NCT04478279
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: A Phase I study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma
Clinical Trial #: 18-048 BrainUp
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820


Study: A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Clinical Trial #: NRG-BN007
NCT #: NCT04396860
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Clinical Trial #: EAF151 20-062
NCT #: NCT03115333
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Clinical Trial #: NRG-BN009
NCT #: NCT04588246
Principal Investigator: Dr. Gondi 1
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Clinical Trial #: NU18C02
NCT #: NCT04047706
Principal Investigator: Dr. Buerki
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to intermediate Grade Gliomas.
Clinical Trial #: NRG-BN005
NCT #: NCT03180502
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2


Study: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Clinical Trial #: NRG-BN003
NCT #: NCT03180268
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov2

Study: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Clinical Trial #: S2212
NCT #: NCT05929768
Principal Investigator: Dr. Flaum
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Clinical Trial #: DRUG GS-US-592-6173
NCT #: NCT05382286
Principal Investigator: William Gradishar, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Clinical Trial #: DRUG GS-US-592-6173
NCT #: NCT05382286
Principal Investigator: William Gradishar, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti PD(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 (ASCENT-03)
Clinical Trial #: DRUG GS-US-592-6238
NCT #: NCT05382299
Principal Investigator: William Gradishar, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
Clinical Trial #: NRG-BR008
NCT #: NCT05705401
Principal Investigator: Eric Donnelly, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase III Clinical Trial Evaluating De-escalation Of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer (DEBRA)
Clinical Trial #: NRG-BR007
NCT #: NCT04852887
Principal Investigator: Dr. Donnelly
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Clinical Trial #: S2007
NCT#: NCT04647916
Principal Investigator: Dr. Ami Shah
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA): A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.
Clinical Trial #: TOL2506 OVELIA 21-041
NCT#: NCT04906395
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Clinical Trial #: A011801 22-011
NCT#: NCT04457596
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.
Clinical Trial #: NU 15B06
NCT Number: NCT02694809
Principal Investigator: Mary Ahn, MD
Contact: Research Office 630.352.5362

Learn more at Clinicaltrials.gov


Study: PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL
Clinical Trial #: RTOG3510/PCORI
NCT Number: NCT02603341
Principal Investigator: Dr. Thukral
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Clinical Trial #: CCTG MA.39
NCT Number: NCT03488693
Principal Investigator: Dr. Thukral
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Clinical Trial #: NRG-GI008
NCT Number: NCT05174169
Principal Investigator: Dr. Mary Mulcahy
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Clinical Trial #: EA2183
NCT#: NCT04248452
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820


Learn more at Clinicaltrials.gov

Study: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Clinical Trial #: NRG GI006
NCT Number: NCT03801876
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Clinical Trial #: EA2197
NCT#: NCT04559139
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Renal

Study: A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Clinical Trial #: S2200
NCT #: NCT05411081
Principal Investigator: Dr. Shenoy
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)
Clinical Trial #: S1931
NCT Number: NCT04510597
Principal Investigator: Dr. Jeffrey Sosman
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: (PDIGEE) PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer
Clinical Trial #: A031704
NCT Number: NCT03793166
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Clinical Trial #: NRG-GU012
NCT Number: NCT05327686
Principal Investigator: Dr. Sean Sachdev
Contact: Research Office (630) 933-7820

Learn more at Clinicaltrials.gov

Please check back

Study: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Clinical Trial #: LU008
NCT Number: NCT05624996
Principal Investigator: Dr. Abazeed
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Clinical Trial #: S1900G
NCT Number: NCT05642572
Principal Investigator: Young Chae, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Clinical Trial #: A082002
NCT Number: NCT04929041
Principal Investigator: Young Chae, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Clinical Trial #: S2302
NCT Number: NCT05633602
Principal Investigator: Young Chae, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Clinical Trial #: EA5181
NCT Number: NCT04092283
Principal Investigator: Nisha Mohindra, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Clinical Trial #: EA3191
NCT Number: NCT04671667
Principal Investigator: Dr. Jochen Lorch
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Clinical Trial #: A151216
NCT Number: NCT02194738
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Clinical Trial #: E4512
NCT Number: NCT02201992
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Solid Tumors

Study: The OncoSET Program Database and Biobank -Combining Clinical Outcomes with Next Generation Sequencing and other Advanced Molecular Testing for Genetic Aberrations in Patients with Advanced Solid Malignancies
Clinical Trial #: NUDB 16Z01 (OncoSET)
Principal Investigator: David Vanderweele, MD
Contact: Research Office 630.933.7820

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Study: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
Clinical Trial #: EAY191 (ComboMATCH)
NCT #: NCT05564377
Principal Investigator: Devalingam Mahalingam, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Other

Study: Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
Clinical Trial #: A092105
NCT #: NCT06010095
Principal Investigator: Dr. Lorch
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Other

Study: Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients treated with Radiation Therapy
Clinical Trial #: NU MGH13Z01
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820

Other

Study: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Clinical Trial #: S2012
NCT #: NCT05058651
Principal Investigator: Mary F. Mulcahy, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Other

Study: A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma
Clinical Trial #: A092107
NCT #: NCT05694871
Principal Investigator: Pedro Antonio Hermida de Viveiros, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Sarcomatoid Mesothelioma

Study: Multimodality Therapy with Immunotherapy in Stage I-IIIA Sarcomatoid Mesothelioma
Clinical Trial #: A082101
NCT #: NCT05647265
Principal Investigator: Young Chae, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Metastatic Urothelial Carcinoma

Study: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
Clinical Trial #: A032001
NCT #: NCT05092958
Principal Investigator: Sarah E. Fenton, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Oropharyngeal

Study: SPECT-CT Guided Elective Contralateral Neck Treatment [SELECT] for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial
Clinical Trial #: CCTG HN11
NCT #: NCT05451004
Principal Investigator: Katelyn Stepan, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Germ Cell Tumors

Study: A Prospective Observational Cohort Study to Assess mRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Clinical Trial #: S1823
NCT #: NCT04435756
Principal Investigator: Dr. Kundu
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Squamous Cell Carcinoma

Study: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Clinical Trial #: EA3191
NCT #: NCT04671667
Principal Investigator: Jochen Lorch, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Squamous Cell Carcinoma

Study: A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Clinical Trial #: EA2182
NCT #: NCT04166318
Principal Investigator: Dr. Kircher
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Myelodysplastic Syndromes

Study: he National Myelodysplastic Syndromes (MDS) Study
Clinical Trial #: NHLBI-MDS
NCT#: NCT02775383
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Multiple Myeloma

Study: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Clinical Trial #: EAA181
NCT Number: NCT04566328
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Pediatric Proton Consortium Registry (PPCR)

Study: A multi-center registry of pediatric patients treated with proton radiation therapy.
Clinical Trial #: 12-103
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Registry

Study: Evaluation tracking project: a prospective chart review of patients treated with proton therapy.
Clinical Trial #: REG001-09
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

Cross-disease sites

Study: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Clinical Trial #: MTG
Principal Investigator: Dr. Abad

Study: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Clinical Trial #: S2104
NCT #: NCT05040360
Principal Investigator: Dr. Mulcahy
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Clinical Trial #: A021806
NCT Number: NCT04340141
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
Clinical Trial #: PAN009-18
NCT Number: NCT02598349
Principal Investigator: Dr. Mohammed
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Evaluating the Response to Neoadjuvant Chemotherapy with Circulating Tumor DNA in Pancreatic Cancer
Clinical Trial #: ctDNA
NCT Number: NCT04616131
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Clinical Trial #: EA2186
NCT Number: NCT04233866
Principal Investigator: Kevin Dawravoo, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Clinical Trial #: EA2185
NCT Number: NCT04239573
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Trial #: DRUG CURLU177PSM0001
NCT #: NCT05204927
Principal Investigator: David Vanderweele, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: A Randomized Phase II study of ADT + Abiraterone versus ADT + Docetaxel + Abiraterone in Patients with Low Volume Metastatic Hormone Sensitive Prostate Cancer
Clinical Trial #: NU 23U08
NCT #: NCT06060587
Principal Investigator: Sarah E. Fenton, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
Clinical Trial #: PCG-GU010-18
NCT #: NCT00969111
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Clinical Trial #: NRG-GU009
NCT#: NCT04513717
Principal Investigator: Dr. Sean Sachdev
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Phase III Study of Image Guided Radiation Therapy with or without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
Clinical Trial #: GU003-10
NCT#: NCT01492972
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
Clinical Trial #: NRG-GU010
NCT#: NCT05050084
Principal Investigator: Sean Sachdev
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Clinical Trial #: EA8191
NCT#: NCT04423211
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Study: (IRONMAN) International Registry for Men with Advanced Prostate Cancer.
Clinical Trial #: c16-170
NCT Number: NCT03151629
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Clinical Trial #: S2015
Principal Investigator: Dr. Wayne
Contact: Research Office 630.933.7820

Endometrial

Study: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Clinical Trial #: GY018
NCT #: NCT03914612
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Endometrial

Study: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Clinical Trial #: NRG-GY026
NCT #: NCt05256225
Principal Investigator: Emily Hinchcliff
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian

Study: Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapy
Clinical Trial #: DRUG IMGN853-0420
NCT #: NCT05456685
Principal Investigator: Dario Roque, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian

Study: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Clinical Trial #: NRG-CC008
NCT #: NCT04251052
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov


Ovarian or Peritoneum

Study: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Clinical Trial #: NRG-GY019
NCT Number: NCT04095364
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Current Northwestern Medicine Proton Center Clinical Trials

If you are interested in learning more about our trials, please contact your physician or visit the proton center website. If you are eligible for a proton therapy clinical trial as a patient at the Proton Center, someone from our team will likely reach out to you to communicate the details of the study.